Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy.
A novel insulin sensitizing agent, thiazolidine, has been demonstrated to inhibit the growth of cultured vascular smooth muscle cells (VSMC) in vitro. This study was undertaken to examine the in vivo effects of the thiazolidine compound pioglitazone (PIO) on carotid neointimal thickening, after endothelial injury in Wistar rats and vascular hypertrophy in stroke-prone spontaneously hypertensive rats (SHR-SP/Izm). PIO treatment (3 mg/kg/day for 1 week prior to endothelial injury and 2 weeks postendothelial injury) remarkably decreased neointimal cross-sectional areas in treated animals (63.8 +/- 4.9 x 10(3) microm2) versus controls (196 +/- 7.6 x 10(3) microm2, P < 0.05). Bromodeoxyuridine uptake in the neointima, a marker of DNA synthesis, was also decreased after treatment compared with controls. In SHR-SP/Izm but not in Wistar rats, PIO treatment decreased blood pressure and plasma insulin levels. PIO treatment in SHR-SP/Izm (3 mg/kg/day from 4 weeks of age for 7 weeks) significantly decreased the medial wall thickness of the mesenteric artery (10.4 +/- 1.2 x 10(3) microm2 versus control, 21.2 +/- 2.4 x 10(3) microm2, P < 0.05). In addition, PIO treatment significantly decreased the expression of EIIIA fibronectin both in the carotid neointima of Wistar rats and the media of the mesenteric artery in SHR-SP/Izm compared with their respective controls (P < 0.05). These results suggest that PIO has vasculo-protective effects in both acute and chronic vascular injury in vivo through inhibition of VSMC proliferation.
Yoshimoto
T
T
Department of Medicine, Institute of Clinical Endocrinology, Tokyo Women's Medical University, Japan. rxk00525@niftyserve.or.jp
Naruse
M
M
Shizume
H
H
Naruse
K
K
Tanabe
A
A
Tanaka
M
M
Tago
K
K
Irie
K
K
Muraki
T
T
Demura
H
H
Zardi
L
L
D000818:Animals; D001012:Aorta, Abdominal / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D001161:Arteriosclerosis / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D001973:Bromodeoxyuridine / Q000378:metabolism; D002339:Carotid Arteries / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002455:Cell Division / Q000187:drug effects / Q000235:genetics; D004247:DNA / Q000096:biosynthesis; D005353:Fibronectins / Q000037:antagonists & inhibitors / Q000378:metabolism; D006973:Hypertension / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*; D006984:Hypertrophy / Q000473:pathology / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male; D008638:Mesenteric Arteries / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D000077205:Pioglitazone; D011897:Random Allocation; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D013844:Thiazoles / Q000627:therapeutic use*; D045162:Thiazolidinediones; D017539:Tunica Intima / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology
D005353:Fibronectins; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D004247:DNA; D001973:Bromodeoxyuridine; D000077205:Pioglitazone